POMC and neoplasm: The different exposure to glucocorticoids of an ACTH-secreting tumor, that can change during the patient clinical management, might thus affect β-arrestins expression and consequently SSTR5 desensitization, endocytosis and signaling, affecting the responsiveness to pasireotide.